PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced the presentation of Phase 2 clinical data for D-PLEX₁₀₀ aimed at preventing surgical wound infections, including those caused by multi-drug resistant organisms. This will occur at the International Orthopaedic Trauma Association meeting from December 14-16, 2022, in Amsterdam. The presentation, titled 'Surgical wound infection reduction with locally administered product releasing doxycycline,' will be delivered by Chief Scientific Officer Noam Emanuel. D-PLEX₁₀₀ is currently in Phase 3 trials for soft tissue infections.

Positive

• Presentation of promising Phase 2 data for D-PLEX₁₀₀ at a significant medical conference.
• D-PLEX₁₀₀ is in Phase 3 clinical trials, indicating progress toward market introduction.

Negative

• None.

D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be Presented During a Podium Presentation

PETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX₁₀₀ will be highlighted in a podium presentation at the first triennial International Orthopaedic Trauma Association meeting being held on December 14-16, 2022, at the RAI Amsterdam Exhibition and Conference Center in Amsterdam, The Netherlands.

First Triennial Meeting of the International Orthopaedic Trauma Association:

Presentation Title:	Surgical wound infection reduction with locally administered product releasing doxycycline - Implications for orthopaedic trauma injuries
Presenter:	Noam Emanuel, PhD., Chief Scientific Officer, PolyPid Ltd.
Date/Time:	Thursday, December 15, 2022, Infection, wound treatment Session, 8:00 a.m. – 9:00 a.m., room E-108

The abstract will be available on www.polypid.com once the conference concludes.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@polypid.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

What is the significance of the D-PLEX100 presentation at the International Orthopaedic Trauma Association meeting?

The presentation highlights Phase 2 clinical data on D-PLEX100's efficacy in preventing surgical infections, which could influence its market acceptance.

When will the D-PLEX100 presentation take place?

The presentation is scheduled for December 15, 2022, during the Infection, wound treatment session.

What is the current status of D-PLEX100 in clinical trials?

D-PLEX100 is in Phase 3 clinical trials aimed at reducing surgical site infections.

How does D-PLEX100 work to prevent infections?

D-PLEX100 releases doxycycline locally to reduce the risk of surgical wound infections, including those from multi-drug resistant organisms.